# GlaxoSmithKline Pharmaceuticals Limited (GLAXO)

> GLAXO closed at ₹2,508.70 on 30 Oct 2026, trailing P/E 39.8, market cap ₹42,500 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO) closed at ₹2,508.70 on 30 Oct 2026, -8.5% over one year, against a 52-week range of ₹2,088.10 – ₹3,120.70.

In the quarter ended 30 Jun 2026 (consolidated, filed 3 Aug 2026) it reported revenue of ₹938 cr and net profit of ₹237 cr, a 25.3% net margin; revenue grew 16.6% and profit grew 15.6% year on year.

On four consecutive filed quarters its trailing P/E is 39.8; since 13 May 2025 its own P/E has ranged from 35.0 to 63.6 (median 45.6), and today's reading is higher than 17% of those 363 trading days.

From the balance sheet dated 31 Mar 2026: return on equity 41.8%, ROCE 50.8%, debt-to-equity 0.00, Piotroski F-score 7 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 87% of 63 sector peers; PBT margin higher than 89% of 63 sector peers; ROE higher than 98% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹2,508.70 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -11.3% / +1.5% / -8.5% |
| 52-week low – high | ₹2,088.10 – ₹3,120.70 |
| Market capitalisation | ₹42,500 cr |
| Trailing P/E | 39.8 |
| Price / book | 18.74 |
| EV / EBITDA | 27.2 |
| Earnings yield | 2.5% |
| TTM EPS | ₹63.05 |
| TTM net profit | ₹1,068 cr |
| Quarter revenue | ₹938 cr |
| Quarter net profit | ₹237 cr |
| Net margin | 25.3% |
| Revenue growth (YoY) | +16.6% |
| Profit growth (YoY) | +15.6% |
| Return on equity | 41.8% |
| ROCE | 50.8% |
| Debt / equity | 0.00 |
| Current ratio | 2.13 |
| Free cash flow | ₹848 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹14.5 cr |

## Questions

### What is the P/E ratio of GlaxoSmithKline Pharmaceuticals Limited?

GlaxoSmithKline Pharmaceuticals Limited's trailing P/E is 39.8, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 13 May 2025 its P/E has ranged 35.0–63.6.

### What were GlaxoSmithKline Pharmaceuticals Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, GlaxoSmithKline Pharmaceuticals Limited reported revenue of ₹938 cr and net profit of ₹237 cr (consolidated), filed with the exchange on 3 Aug 2026.

### What is GlaxoSmithKline Pharmaceuticals Limited's ROE?

Return on equity is 41.8% based on the balance sheet dated 31 Mar 2026.

### Does GlaxoSmithKline Pharmaceuticals Limited have debt?

Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.

### What is GLAXO's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, GLAXO traded between ₹2,088.10 and ₹3,120.70.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/GLAXO

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._